NASDAQ:CAPR - Capricor Therapeutics Stock Price, Price Target & More

Capricor Therapeutics trades on the NASDAQ under the ticker symbol "CAPR."

Capricor Therapeutics Inc (NASDAQ:CAPR) posted its quarterly earnings data on Thursday, May, 10th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.03. The biotechnology company earned $0.40 million during the quarter, compared to analyst estimates of $0.49 million. Capricor Therapeutics had a net margin of 110.98% and a negative return on equity of 485.43%. View Capricor Therapeutics' Earnings History.

Capricor Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Capricor Therapeutics.

3 brokerages have issued 12-month target prices for Capricor Therapeutics' stock. Their predictions range from $2.15 to $9.00. On average, they expect Capricor Therapeutics' share price to reach $6.05 in the next twelve months. This suggests a possible upside of 351.5% from the stock's current price. View Analyst Ratings for Capricor Therapeutics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Capricor Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Capricor Therapeutics include Acer Therapeutics (ACER), Aldeyra Therapeutics (ALDX), Calithera Biosciences (CALA), Tetraphase Pharmaceuticals (TTPH), Eleven Biotherapeutics (EBIO), Chembio Diagnostics (CEMI), MEI Pharma (MEIP), Bellerophon Therapeutics (BLPH), Spring Bank Pharmaceuticals (SBPH), AcelRx Pharmaceuticals (ACRX), XBiotech (XBIT), Intec Pharma (NTEC), Fortress Biotech (FBIO), Emisphere Technologies (EMIS) and Catalyst Biosciences (CBIO).

News headlines about CAPR stock have trended somewhat negative recently, according to Accern. The research firm identifies positive and negative media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Capricor Therapeutics earned a media sentiment score of -0.15 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 48.72 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Shares of CAPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CAPR stock can currently be purchased for approximately $1.34.

Capricor Therapeutics has a market capitalization of $41.04 million and generates $2.67 million in revenue each year. The biotechnology company earns $2.43 million in net income (profit) each year or ($0.44) on an earnings per share basis. Capricor Therapeutics employs 40 workers across the globe.

Capricor Therapeutics' mailing address is 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211. The biotechnology company can be reached via phone at 310-358-3200 or via email at [email protected]